Grace Therapeutics, Inc. Email Format

Biotechnology ResearchQuebec, Canada11-50 Employees

Acasti Pharma, Inc. is a late-stage biotechnology company focused on developing and delivering therapies for rare and orphan diseases. Its portfolio centers on novel drug delivery approaches that aim to improve existing therapies by enabling faster onset, enhanced efficacy, and reduced side effects, potentially improving patient adherence and outcomes. The company targets well-understood conditions with limited or no effective treatments, initially focusing on three underserved orphan diseases: Subarachnoid Hemorrhage, Ataxia Telangiectasia, and Postherpetic Neuralgia. Based in Laval, Quebec, Acasti operates within the biotechnology research sector and holds multiple orphan designation statuses from the FDA, alongside a broad patent protection strategy. Recent developments include ongoing collaboration and trial activities related to its lead injectable nimodipine formulation for aneurysmal subarachnoid hemorrhage, reflecting its continued pursuit of late-stage clinical progress in its chosen indications.

Get verified Grace Therapeutics, Inc. emails free

Company overview Employee directory